Table 3 Treatment-related adverse events
Events, n (%)a | Arm A (n = 30) | Arm B (n = 21) | ||
|---|---|---|---|---|
Any grade | Grade ≥ 3 | Any grade | Grade ≥ 3 | |
Any | 24 (80.0) | 8 (26.7) | 18 (85.7) | 3 (14.3) |
White blood cell count decreased | 10 (33.3) | 2 (6.7) | 0 | 0 |
Anemia | 9 (30.0) | 2 (6.7) | 2 (9.5) | 0 |
Alanine aminotransferase increased | 9 (30.0) | 1 (3.3) | 3 (14.3) | 2 (9.5) |
Neutrophil count decreased | 8 (26.7) | 5 (16.7) | 1 (4.8) | 0 |
Platelet count decreased | 8 (26.7) | 3 (10.0) | 0 | 0 |
Gamma-glutamyltransferase increased | 8 (26.7) | 1 (3.3) | 3 (14.3) | 0 |
Aspartate aminotransferase increased | 5 (16.7) | 0 | 3 (14.3) | 1 (4.8) |
Alkaline phosphatase increased | 3 (10.0) | 1 (3.3) | 1 (4.8) | 0 |
Pruritus | 2 (6.7) | 0 | 1 (4.8) | 0 |
Proteinuria | 2 (6.7) | 0 | 2 (9.5) | 0 |
Lymphocyte count decreased | 2 (6.7) | 0 | 0 | 0 |
Reactive cutaneous capillary endothelial proliferation | 1 (3.3) | 0 | 5 (23.8) | 0 |
Blood bilirubin increased | 1 (3.3) | 0 | 1 (4.8) | 1 (4.8) |
Autoimmune hepatitis | 1 (3.3) | 1 (3.3) | 0 | 0 |
Hyperuricemia | 0 | 0 | 3 (14.3) | 0 |
Blood glucose increased | 0 | 0 | 3 (14.3) | 0 |
Blood lactate dehydrogenase increased | 0 | 0 | 2 (9.5) | 0 |
